Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) witnessed a selling pressure and the shares last traded with a loss of -1.44 points or -1.66% at $85.28. Investors jumped in to buy the shares on weakness. The net money flow till latest update was calculated at $12.15 million with an inflow of $46.46 million in upticks and an outflow of $34.31 million in downticks. Using the data, the up/down ratio is found to be 1.35. The share price has recorded -1.67% on a weekly basis.A block trade of $14.24 million in uptick and $1.44 million in downtick was also observed, resulting in an up/down ratio of 9.88. The net money flow of the block trade stood at a $12.8, signaling heavy buying.
The stock has recorded a 20-day Moving Average of 6.53% and the 50-Day Moving Average is 1.89%. The company shares have dropped 34.11% in the past 52 Weeks. On August 10, 2015 The shares registered one year high of $143.45 and one year low was seen on March 17, 2016 at $75.9. The 50-day moving average is $87.85 and the 200 day moving average is recorded at $93.27. S&P 500 has rallied 1.93% during the last 52-weeks.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): The stock opened at $86.80 on Tuesday but the bulls could not build on the opening and the stock topped out at $87.64 for the day. The stock traded down to $83.50 during the day, due to lack of any buying support eventually closed down at $85.28 with a loss of -1.66% for the day. The stock had closed at $86.72 on the previous day. The total traded volume was 1,881,940 shares.
Currently the company Insiders own 1.8% of Vertex Pharmaceuticals Incorporated shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.03% . Institutional Investors own 97.01% of Vertex Pharmaceuticals Incorporated shares. During last six month period, the net percent change held by insiders has seen a change of -3.03%. On the companys insider trading activities, The director, of Vertex Pharmaceuticals Inc / Ma, Boger Joshua S had unloaded 5,130 shares at $91.18 per share in a transaction on June 15, 2016. The total value of transaction was $467,753. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.